{
    "relevance_rule": {
        "rule_text": "Abstract with Client given keywords",
        "approach": "keywords",
        "key_concepts": {
            "keywords": [
                "Adagrasib", "ALTA3263", "AMG 410", "AMG-510", "ASP3082", "ASP4396", "AST-24081", "Avutometinib", "AZD0022", "BBO-10203", "BBO-11818", "BBO-8520", "Beta catenin", "BGB-53038", "BI 3706674", "BRSD-143", "BTDX-4933", "CHK1", "Colorectal Cancer", "CypA", "D3S-001", "D3S-001_", "ELI-002", "ERAS-0015", "ERAS-4001", "FKBP", "FMC-376", "fulzerasib", "G12", "G12A", "G12C", "G12D", "G12E", "G12F", "G12I", "G12L", "G12N", "G12R", "G12S", "G12V", "G13", "G13C", "G13D", "G13N", "G13P", "G13R", "G13S", "G13V", "Garsorasib", "GDC-6036", "GDC-7035", "HBI-2438_", "HRAS", "HRS-4642", "INCB161734", "INCB186748", "Ivonescimab", "JAB21822", "JAB-23E73", "JYP0015", "KRAS", "KRAS-Multi", "LY-3537982", "LY3962673", "LY4066434", "MK-1084", "MYC", "Non-Small Cell Lung Cancer", "NRAS", "Onvansertib", "Pancreatic Cancer", "Pancreatic Ductal Adenocarcinoma", "Pan-KRAS", "Pan-RAS", "PAX8", "PF-07934040", "PF-07985045", "PKN2", "PT886", "PTK2", "Q61", "Q61E", "Q61H", "Q61K", "Q61L", "Q61P", "Q61R", "QTX3034", "QTX3046", "QTX3544", "Quemliclustat", "RAF1", "RAS", "RAS Wild-type", "RAS(off)", "RAS(off) Mutations", "RAS(ON)", "RAS(on) Mutations", "RAS-multi", "RMC-6236", "RMC-6291", "RMC-9805", "RO7673396", "SHOC2", "sosimerasib", "STK7", "TP53", "TSN1611", "VS-7375", "VVD-159642", "Zolbetuximab"
            ],
            "categories": [
                "Competitors", "Research", "Tumor Type", "Genotype"
            ],
            "contextual_concepts": []
        },
        "reasoning": "This rule filters all abstracts to only those containing client-specified keywords, serving as the main relevance filter."
    },
    "priority_rules": [
        {
            "priority": "High",
            "rule_text": "1. All abstracts with mentions of competitors\n2. Abstracts with tumor types in combination with client specified genotypes\n3. Abstracts mentioning K(RAS) mutant + tumor types.\n4. All abstracts with mentions of research keywords.\nExclude KRAS/RAS wild type abstracts",
            "approach": "keywords",
            "key_concepts": {
                "keywords": [
                    // Competitor keywords
                    "Adagrasib", "ALTA3263", "AMG 410", "AMG-510", "ASP3082", "ASP4396", "AST-24081", "Avutometinib", "AZD0022", "BBO-10203", "BBO-11818", "BBO-8520", "BGB-53038", "BI 3706674", "BRSD-143", "BTDX-4933", "D3S-001", "D3S-001_", "ELI-002", "ERAS-0015", "ERAS-4001", "FMC-376", "fulzerasib", "Garsorasib", "GDC-6036", "GDC-7035", "HBI-2438_", "HRS-4642", "INCB161734", "INCB186748", "Ivonescimab", "JAB21822", "JAB-23E73", "JYP0015", "LY-3537982", "LY3962673", "LY4066434", "MK-1084", "Onvansertib", "PF-07934040", "PF-07985045", "PT886", "QTX3034", "QTX3046", "QTX3544", "Quemliclustat", "RMC-6236", "RMC-6291", "RMC-9805", "RO7673396", "sosimerasib", "TSN1611", "VS-7375", "VVD-159642", "Zolbetuximab",
                    // Tumor types
                    "Colorectal Cancer", "Non-Small Cell Lung Cancer", "Pancreatic Cancer", "Pancreatic Ductal Adenocarcinoma",
                    // Genotypes
                    "G12", "G12A", "G12C", "G12D", "G12E", "G12F", "G12I", "G12L", "G12N", "G12R", "G12S", "G12V", "G13", "G13C", "G13D", "G13N", "G13P", "G13R", "G13S", "G13V", "HRAS", "KRAS", "KRAS-Multi", "NRAS", "Pan-KRAS", "Pan-RAS", "Q61", "Q61E", "Q61H", "Q61K", "Q61L", "Q61P", "Q61R", "RAS", "RAS Wild-type", "RAS(off)", "RAS(off) Mutations", "RAS(ON)", "RAS(on) Mutations", "RAS-multi",
                    // Research keywords
                    "Beta catenin", "CHK1", "CypA", "FKBP", "MYC", "PAX8", "PKN2", "PTK2", "RAF1", "SHOC2", "STK7", "TP53"
                ],
                "categories": [
                    "Competitors", "Tumor Type", "Genotype", "Research"
                ],
                "contextual_concepts": [
                    "K(RAS) mutant", "tumor types", "combination of tumor type and genotype"
                ]
            },
            "exclusions": [
                "KRAS wild type", "RAS wild type", "K(RAS) wild type"
            ],
            "reasoning": "This rule is based on explicit keyword matching for competitors, tumor type + genotype combinations, K(RAS) mutant + tumor types, and research keywords. Excludes wild type mentions to ensure only mutant contexts are prioritized."
        },
        {
            "priority": "Medium",
            "rule_text": "1. All abstracts with mentions of genotypes (excluding those with tumor types in combination with client specified genotypes, K(RAS) mutant + tumor types, or research keywords)\n2. Abstracts mentioning (K)RAS wild type + tumor type.",
            "approach": "keywords",
            "key_concepts": {
                "keywords": [
                    // Genotypes
                    "G12", "G12A", "G12C", "G12D", "G12E", "G12F", "G12I", "G12L", "G12N", "G12R", "G12S", "G12V", "G13", "G13C", "G13D", "G13N", "G13P", "G13R", "G13S", "G13V", "HRAS", "KRAS", "KRAS-Multi", "NRAS", "Pan-KRAS", "Pan-RAS", "Q61", "Q61E", "Q61H", "Q61K", "Q61L", "Q61P", "Q61R", "RAS", "RAS Wild-type", "RAS(off)", "RAS(off) Mutations", "RAS(ON)", "RAS(on) Mutations", "RAS-multi"
                ],
                "categories": [
                    "Genotype"
                ],
                "contextual_concepts": [
                    "(K)RAS wild type + tumor type"
                ]
            },
            "exclusions": [
                // Exclude abstracts that fit High priority: competitors, tumor type + genotype, K(RAS) mutant + tumor types, research keywords
                "Adagrasib", "ALTA3263", "AMG 410", "AMG-510", "ASP3082", "ASP4396", "AST-24081", "Avutometinib", "AZD0022", "BBO-10203", "BBO-11818", "BBO-8520", "BGB-53038", "BI 3706674", "BRSD-143", "BTDX-4933", "D3S-001", "D3S-001_", "ELI-002", "ERAS-0015", "ERAS-4001", "FMC-376", "fulzerasib", "Garsorasib", "GDC-6036", "GDC-7035", "HBI-2438_", "HRS-4642", "INCB161734", "INCB186748", "Ivonescimab", "JAB21822", "JAB-23E73", "JYP0015", "LY-3537982", "LY3962673", "LY4066434", "MK-1084", "Onvansertib", "PF-07934040", "PF-07985045", "PT886", "QTX3034", "QTX3046", "QTX3544", "Quemliclustat", "RMC-6236", "RMC-6291", "RMC-9805", "RO7673396", "sosimerasib", "TSN1611", "VS-7375", "VVD-159642", "Zolbetuximab",
                "Colorectal Cancer", "Non-Small Cell Lung Cancer", "Pancreatic Cancer", "Pancreatic Ductal Adenocarcinoma",
                "Beta catenin", "CHK1", "CypA", "FKBP", "MYC", "PAX8", "PKN2", "PTK2", "RAF1", "SHOC2", "STK7", "TP53",
                "K(RAS) mutant"
            ],
            "reasoning": "This rule is for abstracts mentioning genotypes, but not those already captured by the High priority rule (i.e., not in combination with tumor types, not mentioning competitors, not research keywords, not K(RAS) mutant + tumor types)."
        },
        {
            "priority": "Low",
            "rule_text": "Abstracts with tumor types (excluding those with competitors, research keywords, genotypes, or any combination of tumor type and genotype, K(RAS) mutant + tumor types, or (K)RAS wild type + tumor type).",
            "approach": "keywords",
            "key_concepts": {
                "keywords": [
                    "Colorectal Cancer", "Non-Small Cell Lung Cancer", "Pancreatic Cancer", "Pancreatic Ductal Adenocarcinoma"
                ],
                "categories": [
                    "Tumor Type"
                ],
                "contextual_concepts": []
            },
            "exclusions": [
                // Exclude all higher priority concepts
                "Adagrasib", "ALTA3263", "AMG 410", "AMG-510", "ASP3082", "ASP4396", "AST-24081", "Avutometinib", "AZD0022", "BBO-10203", "BBO-11818", "BBO-8520", "BGB-53038", "BI 3706674", "BRSD-143", "BTDX-4933", "D3S-001", "D3S-001_", "ELI-002", "ERAS-0015", "ERAS-4001", "FMC-376", "fulzerasib", "Garsorasib", "GDC-6036", "GDC-7035", "HBI-2438_", "HRS-4642", "INCB161734", "INCB186748", "Ivonescimab", "JAB21822", "JAB-23E73", "JYP0015", "LY-3537982", "LY3962673", "LY4066434", "MK-1084", "Onvansertib", "PF-07934040", "PF-07985045", "PT886", "QTX3034", "QTX3046", "QTX3544", "Quemliclustat", "RMC-6236", "RMC-6291", "RMC-9805", "RO7673396", "sosimerasib", "TSN1611", "VS-7375", "VVD-159642", "Zolbetuximab",
                "G12", "G12A", "G12C", "G12D", "G12E", "G12F", "G12I", "G12L", "G12N", "G12R", "G12S", "G12V", "G13", "G13C", "G13D", "G13N", "G13P", "G13R", "G13S", "G13V", "HRAS", "KRAS", "KRAS-Multi", "NRAS", "Pan-KRAS", "Pan-RAS", "Q61", "Q61E", "Q61H", "Q61K", "Q61L", "Q61P", "Q61R", "RAS", "RAS Wild-type", "RAS(off)", "RAS(off) Mutations", "RAS(ON)", "RAS(on) Mutations", "RAS-multi",
                "Beta catenin", "CHK1", "CypA", "FKBP", "MYC", "PAX8", "PKN2", "PTK2", "RAF1", "SHOC2", "STK7", "TP53",
                "K(RAS) mutant", "(K)RAS wild type"
            ],
            "reasoning": "This rule is for abstracts mentioning only tumor types, but not those already captured by higher priority rules (i.e., not mentioning competitors, research keywords, genotypes, or any combination of tumor type and genotype, K(RAS) mutant + tumor types, or (K)RAS wild type + tumor type)."
        }
    ]
}